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ABSTRACT
Objective To determine the extent to which intensive
dietary intervention can influence glycaemic control and
risk factors for cardiovascular disease in patients with
type 2 diabetes who are hyperglycaemic despite
optimised drug treatment.
Design Randomised controlled trial.
Setting Dunedin, New Zealand.
Participants 93 participants aged less than 70 years with
type 2 diabetes and a glycated haemoglobin (HbA1c)o f
more than 7% despite optimised drug treatments plus at
least two of overweight or obesity, hypertension, and
dyslipidaemia.
Intervention Intensive individualised dietary advice
(according to the nutritional recommendations of the
European Association for the Study of Diabetes) for six
months; both the intervention and control participants
continued with their usual medical surveillance.
MainoutcomemeasuresHbA1cwastheprimaryoutcome.
Secondary outcomes included measures of adiposity,
blood pressure, and lipid profile.
Results After adjustment for age, sex, and baseline
measurements, the difference in HbA1c between the
intervention and control groups at six months (−0.4%,
95% confidence interval −0.7% to −0.1%) was highly
statistically significant (P=0.007), as were the decreases
in weight (−1.3 kg, −2.4 to −0.1 kg; P=0.032), body mass
index (−0.5, −0.9 to −0.1; P=0.026), and waist
circumference (−1.6 cm, −2.7 to −0.5 cm; P=0.005). A
decrease in saturated fat (−1.9% total energy, −3.3% to
−0.6%; P=0.006) and an increase in protein (1.6% total
energy, 0.04% to 3.1%; P=0.045) in the intervention
group were the most striking differences in nutritional
intake between the two groups.
Conclusions Intensive dietary advice has the potential to
appreciably improve glycaemic control and
anthropometricmeasuresinpatientswithtype2diabetes
and unsatisfactory HbA1c despite optimised
hypoglycaemic drug treatment.
Trial registration Clinical trials NCT00124553.
INTRODUCTION
Lifestyle modification, in particular recommendations
to follow an appropriate dietary pattern, has generally
beenacceptedasacornerstoneoftreatmentforpeople
with type 2 diabetes, with the expectation that an
appropriate intake of energy and nutrients will
improve glycaemic control and reduce the risk of
complications.
1 However, adherence to healthy life-
style changes is difficult for many people, and taking
tablets is often an easier option.
2
Before the introduction of oral hypoglycaemic
agents, diet and, for a few, insulin were the only avail-
able treatments. During the 1970s the types of diets
prescribed and the degree of adherence varied
widely.
3 Despite many short term studies providing
compelling evidence of the potential for various diet-
ary modifications to improve glycaemic control and
riskfactorsforcardiovasculardisease,
1theappearance
ofneworalhypoglycaemicagents,theincreaseduseof
insulinintype2diabetes,andthefrequentprescription
of statins and antihypertensive agents may have
resulted in further reliance on pharmacological rather
thannutritionaltreatment.
4-7 In parallelwithincreased
prescription of cardioprotective drugs, reductions in
bloodpressureandintotalcholesterolandlowdensity
lipoprotein cholesterol have been seen in people with
type 2 diabetes.
689Measures of adiposity and glycae-
mic control have deteriorated over the same period,
however.
6Theobservationofaninexorabledeteriora-
tion in glycaemic control regardless of the nature of
hypoglycaemic drug treatment during the United
Kingdom Prospective Diabetes Study (UKPDS),
10
and the reluctance among some patients to sufficiently
alter lifestyle practices,
1112 may further explain a pre-
ference for drugs over dietary advice. The potential of
dipeptidyl-peptidase IV inhibitors, a costly new phar-
macological approach, to produce modest reductions
in glycatedhaemoglobin(HbA1c) in patientswith type
2 diabetes on maximum doses of conventional treat-
ments seems likely to perpetuate this trend.
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mally tolerated sulphonylureasand metformin has the
potential for additional weight gain and increased risk
of hypoglycaemic episodes.
14
The major studies that showed the benefits of diet
treatment were carried out before the recommenda-
tions that led to the greatly increased prescription of
hypoglycaemic and cardioprotective drugs and were
of short duration.
15-19 The Lifestyle Over and Above
Drugs in Diabetes (LOADD) study therefore investi-
gated the extent to which intensive evidence based
dietary advice is able to influence glycaemic control
and risk factors for cardiovascular disease in people
with type 2 diabetes who had persistent hyperglycae-
mia and remained at high cardiovascular risk despite
their drug treatment having been optimised according
to current guidelines.
METHODS
The LOADD study, a randomised controlled trial of
six months’ duration, took place at the Department of
HumanNutrition,UniversityofOtago,Dunedin,New
Zealand, between October 2006 and July 2009.
Participants
We recruited potential participants through local gen-
eral practices, hospital diabetes clinics, the regional
diabetes retinal screening service, pharmacies, and
the local diabetes society and through advertising in
the local weekly newspaper. We required them to be
under 70 years of age, be resident within the Dunedin
city boundary, have been diagnosed with type 2 dia-
betes more than nine months before study entry, and,
despite having been given standard dietary advice by
dietitian,doctor,ornurseandprescribedoralhypogly-
caemicagents,insulin,orboth,havepersistentunsatis-
factoryglycaemiccontroldefinedasHbA1cmorethan
7%. As the study was aimed at people at high risk of
cardiovasculardisease,wealsorequiredparticipantsto
have at least two of the following three characteristics:
overweight or obesity (body mass index ≥25), hyper-
tension (currently prescribed antihypertensive drugs
or blood pressure >140/90 mm Hg despite optimised
antihypertensive drug treatment), and dyslipidaemia
(currently prescribed lipid modifying drugs or one or
more of total cholesterol >5.2 mmol/l, low density
lipoprotein cholesterol >3.5 mmol/l, triglycerides
>2.0 mmol/l, and high density lipoprotein cholesterol
<1.0 mmol/l despite optimised lipid modifying drug
treatment). Pregnancy, the presence of a serious
chronic illness other than diabetes considered likely
to need a start or change of drug treatment during the
trial, or unwillingnessto attempt to comply with inten-
sive dietary advice if randomised to the intervention
group excluded participation.
Potential participants were screened by telephone
by a research nurse or research dietitian and then by
a medical officer during a clinical assessment that
included a blood test for measurements of HbA1c and
fasting lipids. We considered participants suitable for
randomisation to the intervention or control group if
they fulfilled the entry criteria and were receiving
appropriate maximally tolerated classes and doses of
drugtreatmentsforbloodglucose,bloodpressure,and
lipid control according to national and international
guidelines for the management of type 2 diabetes.
17-19
Those who fulfilled the entry criteria but were not
being treated with appropriate drugs or in whom
dosage adjustment was needed were recommended
an optimised treatment regimen. We reassessed their
eligibility for randomisation after stabilisation on their
new treatment regimen, requiring that appropriate
drug treatment had been started and adjusted accord-
ing to guidelines. All clinical assessments and adjust-
ments of treatment were carried out under the
supervision of one of the authors (JM), who has more
than 30 years of experience as a consultant physician
withexpertiseindiabetesandaninvolvementindevel-
oping guidelines nationally and internationally. All
randomised participants were thus considered not to
be well controlled despite receiving optimised drug
treatments.
Randomisation
Tworesearchassistantsnotinvolvedwiththestudydid
the randomisation in blocks of 10 by using sealed opa-
que envelopes and with stratification according to sex
and HbA1c (7-8%, or >8%) measured at the clinical
Assigned to usual
diabetes care (n=52)
Completed 6 months
(n=48; 92%)
Assigned to usual diabetes care
and dietary intervention (n=52)
Assessed for eligibility (n=165)
Had clinical assessment (n=122)
Eligible after clinical assessment (n=105)
Discontinued (n=4):
  Withdrew participation as
    disappointed to be
    control (n=1)
  Loss of family member (n=1)
  Died (n=1)
  Became pregnant (n=1)
Discontinued (n=6):
  Withdrew participation
    (n=2; 1 believed blood
    glucose levels increasing,
   1 disliked dietary advice)
  Moved out of area (n=1)
  Lost to follow-up (n=2)
  Admitted to hospital (n=1)
Completed 6 months
  (n=46; 89%)
Excluded from analysis
  (n=1; misdiagnosis:
  slow onset type 1 diabetes)
Did not meet inclusion criteria (n=43)
Randomised (n=104)
Withdrew as travelling more than expected (n=1)
Excluded (n=17):
  HbA1c ≤7% (n=13)
  Diet only treatment (n=1)
  Too busy with work (n=1)
  Unspecified reason (n=2)
Flow chart of participants.
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The randomisation took place at a separate site, super-
vised by the study statistician.
Intervention
Both groups received one-off “push play” advice on
physical activity—that is, on the desirability of achiev-
ing at least 30 minutes of physical activity of moderate
intensity on most, if not all, days of the week.
20 Both
groupscontinuedtoattendtheirusualproviderofclin-
ical care for diabetes (general practitioner or hospital
diabetes clinic). Participants in the control group were
given an undertaking that they would receive further
advicedependingontheoutcomeofthetrial,andthey
had no further contact with the researchers until they
and those randomised to receive intensive dietary
intervention were reassessed at the end of the six
month trial.
The intensive dietary intervention was based on the
evidence based recommendations of the Diabetes and
Nutrition Study Group of the European Association
fortheStudyofDiabetes.
1Therecommendeddistribu-
tion of macronutrients was protein 10-20% of total
energy,totalfatlessthan30%oftotalenergy,saturated
fatless than10%of totalenergyor lessthan8% oftotal
energy if low density lipoprotein cholesterol was
raised, polyunsaturated fatty acids less than 10% of
totalenergy,andcarbohydrate45-60%oftotalenergy.
The target for dietary fibre intake was 40 g/day—or
20 g/4184 kJ (1000 kcal)—about half of which was
intended to be soluble fibre. For participants who
were overweight or obese, the recommendation was
to achieve modest (at least 5%) weight loss. We trans-
lated recommended total energy intake and nutrient
distribution for each participant into foods, recipes,
and meals on the basis of the initial three day weighed
dietrecord,personalpreference,budget,andsociocul-
tural factors. The emphasis was on appropriate food
quantities, vegetables, fruit, legumes, wholegrain cer-
eals, fish (preferably oily), nuts, low fat dairy products,
and appropriate fats and oils. Meat, when consumed,
was to be lean.
Each participant had two individual sessions with
the study dietitian within the first month after rando-
misation, then monthly sessions for five months. One
group education session within the first two months
and a telephone call between visits, as deemed neces-
sary by the dietitian, provided opportunities to rein-
force the dietary advice and give additional support.
Participants’ family members were encouraged to
attend dietary education sessions. Clinical measure-
ments (anthropometric measures and blood pressure)
and blood tests (HbA1c and lipids) at three months
were an integral component of the six month inter-
vention and provided a means of offering feedback
on progress and further support.
Study outcomes
TheprimaryoutcomemeasurewasHbA1c.Secondary
outcome measures included changes in hypoglycae-
mic drugs (type and dose), weight, body mass index,
waist circumference, blood pressure, fasting plasma
glucose, and lipid profile.
Measurements were made at baseline and six
months. We recorded demographic data at baseline,
a nurse administered a questionnaire on medical his-
tory, drugs, and physical activity, and a dietitian gave
instruction on completion of a three day weighed diet
record (two weekdays and one weekend day) at base-
line and six months. Trained research nurses made
resting blood pressure (triplicate) and anthropometric
(duplicate) measurements under standardised condi-
tionsandtookbloodsamplesaftera10hourovernight
fast. These measurements were made on two separate
occasions(withinoneweek)andaveraged.Bloodsam-
ples were analysed at the Lipid and Diabetes Labora-
tory of the Department of Human Nutrition,
University of Otago, using methods previously
described by our laboratory.
21 Southern Community
Laboratory Dunedin analysed urine samples. Urinary
creatinine was measured on a Roche Hitachi 911 ana-
lyserusingtheJafféreactionmethod.Urinaryalbumin
was assayed on a Roche Modular analyser using the
Tinaquant immuno-turbidmetric assay.
Statistical analysis
We based an estimate of the sample size for the study
on data from the Otago diabetes register.
22 Calcula-
tions used a standard deviation of 1.4% and a correla-
tion between measures of 0.8. We needed to enrol at
least 41 people in each treatment group to detect a dif-
ference of 0.57% in HbA1c with 80% power at the 5%
level of significance allowing for a 10% dropout rate.
23
We analysed the data in accordance with a modified
intentiontotreatprinciple,usingapre-establishedana-
lysis plan. We usedanalysis of covariance,with adjust-
ment for sex, age, and the baseline measure, to
Table 1 |Baseline characteristics of study participants in intervention and control groups.
Values are numbers (percentages) unless stated otherwise
Characteristics
Intervention
(n=45)
Control
(n=48)
Mean (SD) age (years) 56.6 (8.8) 58.4 (8.8)
Women 28 (62) 27 (56)
Self identified ethnicity:
New Zealand European 34 (76) 42 (88)
Ma ¯o r i 1( 2 ) 2( 4 )
Pacific Island 3 (7) 0 (0)
Other 7 (16) 4 (8)
Current smoker 4 (9) 3 (6)
Mean (SD) duration of diabetes (years) 8.7 (6.4) 9.0 (5.8)
Drug groups:
Oral hypoglycaemic agents only 31 (69) 34 (71)
Insulin only 1 (2) 0 (0)
Insulin and oral hypoglycaemic agent(s) 13 (29) 14 (29)
Lipid modifying drugs 26 (58) 31 (65)
Angiotensin converting enzyme inhibitor,
angiotensin II receptor blocker, or both
24 (53) 30 (63)
Other antihypertensive agents 14 (31) 23 (48)
Aspirin 17 (38) 31 (65)
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months. We used two sided significance tests through-
out. The results are presented as differences (with 95%
confidence intervals) between the two groups. We
made no adjustment for multiple testing.
RESULTS
Figure 1 shows the flow of participants through the
study. Of 104 eligible participants randomised, 94
(90%)completedthesixmonthstudy.Table 1provides
key characteristics of the two groups. Most participants
inbothgroupsdescribedthemselvesasNewZealanders
of European descent. However, the intervention group
wasethnicallymorediverse—onequarterwereofMori,
Pacific Island, Lebanese, or Indian ethnicity. Partici-
pants in the intervention group were slightly younger,
but smoking status, duration of diabetes, and use of
hypoglycaemic drugs were similar in the two groups.
Table 2 shows baseline and six month measure-
ments of the primary and secondary end points and
the adjusted differences between the two groups.
Improvements occurred in most clinical and labora-
tory measures in the intervention group, and minimal
changes occurred in the control group. The difference
in HbA1c between the two groups (0.4%) at the end of
the six month intervention after adjustment for base-
line values, age, and sex was highly significant
(P=0.007). Similarly, we saw improvements in anthro-
pometric measures in the intervention group, and dif-
ferences between the two groups were statistically
significant.
Almost a third (n=14; 29%) of the control group had
prescribed doses of hypoglycaemic drugs increased
during the study period compared with four (9%) of
the intervention group. Six (13%) intervention partici-
pants and two (4%) controls had decreases in the dose
of prescribed hypoglycaemic drugs. In the
intervention group, four of the 14 patients on insulin
had theirinsulindosesdecreasedby upto81 units.No
serious adverse events were reported.
Table 3 shows the nutritional intakes calculated for
the 78 participants for whom complete three day
weighed diet records were available at both baseline
and six months. A decrease in saturated fat (P=0.006)
and an increase in dietary protein (P=0.045) were the
moststrikingdifferencesbetweenthetwogroups.Ana-
lysisofthefoodgroupsshowedgreaterconsumptionof
low fat dairy products and nuts in the intervention
group. At six months, a higher proportion of total
energy consumed by intervention participants com-
pared with control participants was from low fat dairy
products(8%v6%totalenergy)andnuts(5%v1%total
energy). In contrast, 7% of total energy among control
participantsand3%oftotalenergyamongintervention
participants was from high fat dairy products.
DISCUSSION
Inthisstudy,intensivenutritiontreatmentachievedan
improvementinbothglycaemiccontrolandanthropo-
metricmeasuresinpatientswithtype2diabetesathigh
risk of cardiovascular disease whose control was con-
sidered to be unsatisfactory despite optimum drug
treatment according to international management
guidelines.
17-19 This effect occurred despite the fact
that some of the patients considered to be on maxi-
mum drug treatment were able to reduce their dose
of tablets or insulin. The magnitude of the reduction
inHbA1c(0.4%)iscomparablewiththatseeninclinical
trialswhenanewdrughasbeenaddedtoconventional
agents.
24-26 For example, the use of vildagliptin
together with insulin results in HbA1c reductions of
0.3% compared with the effects of insulin alone.
25
The reduction in HbA1c may seem to be modest.
However, the relation between HbA1c and
Table 2 |Primary and secondary end points at baseline and six months and adjusted differences between intervention and
control groups. Values are means (SD) unless stated otherwise
Measures
Intervention (n=45) Control (n=48)
Difference* (95% CI) P value* Baseline 6 months Baseline 6 months
HbA1c (%) 8.9 (1.4) 8.4 (1.0) 8.6 (1.3) 8.6 (1.2) −0.4 (−0.7 to −0.1) 0.007
Glucose (mmol/l) 9.0 (2.6) 8.1 (2.2) 8.3 (2.4) 8.3 (2.9) −0.6 (−1.5 to 0.3) 0.181
Weight (kg) 98.4 (18.7) 96.3 (18.0) 95.1 (18.8) 94.5 (18.3) −1.3 (−2.4 to −0.1) 0.032
Body mass index† 35.1 (6.1) 34.3 (5.8) 34.2 (6.0) 34.0 (5.9) −0.5 (−0.9 to −0.1) 0.026
Waist circumference (cm) 111.4 (13.7) 108.9 (13.6) 108.0 (12.8) 107.4 (12.7) −1.6 (−2.7 to −0.5) 0.005
Systolic blood pressure (mm Hg) 131.9 (15.8) 127.8 (15.6) 131.7 (16.1) 129.2 (16.4) −1.4 (−6.1 to 3.2) 0.536
Diastolic blood pressure (mm Hg) 79.8 (9.0) 76.5 (8.7) 79.0 (10.3) 76.4 (10.6) −0.5 (−3.0 to 2.0) 0.673
Total cholesterol (mmol/l) 4.35 (0.93) 4.11 (0.97) 3.93 (0.84) 3.87 (0.94) −0.14 (−0.38 to 0.10) 0.248
HDL cholesterol (mmol/l) 1.04 (0.22) 1.04 (0.25) 1.03 (0.22) 1.01 (0.24) 0.01 (−0.04 to 0.05) 0.747
LDL cholesterol (mmol/l) 2.52 (0.83) 2.30 (0.82) 2.16 (0.71) 2.13 (0.80) −0.15 (−0.35 to 0.06) 0.162
Triglycerides (mmol/l) 1.71 (0.83) 1.67 (1.04) 1.61 (0.65) 1.59 (0.68) 0.01 (−0.26 to 0.28) 0.933
Uric acid (µmol/l) 302.1 (78.9) 313.3 (81.5) 316.2 (74.0) 315.9 (79.5) 11.0 (−3.7 to 25.6) 0.140
Urine albumin:creatinine ratio‡ 7.5 (24.6) 7.1 (23.8) 11.0 (53.1) 5.6 (22.2) 3.4 (−0.5 to 7.4) 0.089
HDL=high density lipoprotein; LDL=low density lipoprotein.
*Adjusted for age, sex, and baseline measurements.
†Calculated as weight in kilograms divided by square of height in metres.
‡Complete urine samples not obtained for two participants in intervention group and one participant in control group; albumin was measured in
milligrams per litre, and creatinine was measured in grams per litre; urine albumin:creatinine ratio values were log transformed.
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reduction in HbA1c is likely to reduce the risk of com-
plications. In the UKPDS, in which no threshold for
risk was seen, each 1% reduction in mean HbA1c was
associated with reductions in risk of 21% for any end
point.
27 As expected from other studies in which
patients with type 2 diabetes on various drugs have
been followed prospectively, participants in the con-
trol group showed no improvement in glycaemic con-
trol, despite increased doses or changes in their
hypoglycaemic drugs.
10 Measures of adiposity
improved in parallel with improvements in HbA1c,
and the differences between the two groups were also
significant. This is in contrast to insulin treatment, of
which weight gain is a common side effect.
14 Failure to
show significant differences in blood pressure or in
total cholesterol and low density lipoprotein choles-
terol between the groups may be due to the fact that
values were close to target levels at the start of the
studyandthatcurrentantihypertensiveandlipidmod-
ifying drugs are effective.
Comparison with other studies
Nutritionalmodificationhasrepeatedlybeenshownto
have the potential to improve glycaemic control and
reduce cardiovascular risk in both type 1 and type 2
diabetes,
151628 but no definitive data show its potential
in the context of intensive drug treatment as currently
recommended. In a small study, Aas and colleagues
suggested that intensive lifestyle intervention was as
effective as insulin in improving glycaemic control in
patients with type 2 diabetes on maximal tolerated
doses of oral hypoglycaemic agents, with additional
benefit in that lifestyle change was associated with
weight loss whereas those randomised to insulin
gained weight.
29 In another small study, Goudswaard
andcolleaguesconfirmedinasimilargroupofpatients
that an intensive educational programme, including
dietary instruction, had the potential to improve gly-
caemiccontroltotheextentthatdelayingtheintroduc-
tion of insulin was considered appropriate.
30 Both the
ICAN study and Look AHEAD study also showed
benefits from a lifestyle intervention among over-
weight and obese patients with type 2 diabetes, but in
thosestudiesthepatientsdidnotnecessarilyhavepoor
glycaemic control and no attempt was made to opti-
mise drug treatment beforehand
2331; weight loss,
rather than glycaemic control, was the primary out-
come. No studies to date have approached the clinical
question considered here, which is increasingly rele-
vant as patients with type 2 diabetes are prescribed an
increasing number of drugs and, like populations of
non-diabeticpeopleworldwide,arebecomingincreas-
ingly overweight and obese.
3233 Excess adiposity is
associatednotonlywithmoredifficulttocontrollevels
of blood glucose and diabetes related complications
butalsowithanincreasedriskofotherseriousmorbid-
ities and mortality, including an increased risk of sev-
eral important cancers.
34
Strengths and limitations of study
Thehighretentionratethroughoutthestudyisamajor
strength, as is the fact that the dietary intervention was
based on internationally accepted guidelines, those of
the Diabetes and Nutrition Study Group of the Eur-
opean Association for the Study of Diabetes.
1 The
non-prescriptive dietary approach, consideration of
participants’ background and socioeconomic circum-
stances, and non-reliance on commercially prepared
meal replacements may have contributed to the high
retention rate. The fact that participants were volun-
teers who were prepared to make substantial lifestyle
changes, as well as the six month duration of the inter-
vention, may be perceived to be weaknesses of the
study. However, a high level of motivation and com-
pliance is an essential prerequisite for all therapeutic
optionsindiabetes,andtheefficacyofthedietaryinter-
ventionwasthefocus,ratherthanitsmaintenance.The
need to explore various approaches to self manage-
ment, including the adoption and maintenance of
nutritional changes, is widely recognised.
35
Implications
The Diabetes and Nutrition Study Group guidelines
are less prescriptive than many earlier sets of dietary
advice.Theyacknowledgethatseveraldietarypatterns
canbeadoptedastreatmentsfortype2diabetes.These
relatively new guidelines emphasise that appropriate
intakes of total energy and a dietary pattern in which
intactfruits,vegetables,wholegraincereals,andlowfat
Table 3 |Nutrient intakes at baseline and six months and adjusted differences between intervention and control groups at
six months. Values are means (SD) unless stated otherwise
Nutrients
Intervention Control
Difference*
(95% CI) P value*
Baseline
(n=39)
6 months
(n=39)
Baseline
(n=39)
6 months
(n=39)
Energy (kJ) 8020 (1899) 6855 (1770) 7845 (2085) 7171 (2087) −334 (−1082 to 414) 0.376
Protein (% TE) 19.7 (3.7) 22.1 (3.9) 19.2 (3.5) 20.4 (4.1) 1.6 (0.04 to 3.1) 0.045
Total fat (% TE) 30.9 (6.1) 28.7 (5.3) 29.8 (6.1) 29.9 (6.6) −1.7 (−4.4 to 1.0) 0.211
Saturated fatty acids (% TE) 11.2 (3.2) 9.7 (2.5) 11.3 (3.5) 11.7 (3.4) −1.9 (−3.3 to −0.6) 0.006
Polyunsaturated fatty acids (% TE) 5.2 (1.6) 5.6 (1.8) 5.1 (2.0) 4.7 (1.9) 1.2 (−0.7 to 3.2) 0.211
Carbohydrate (% TE) 47.5 (7.1) 48.0 (5.3) 50.1 (7.5) 48.5 (7.2) 0.5 (−2.3 to 3.2) 0.731
Dietary fibre (g) 25.7 (6.3) 26.3 (7.3) 26.4 (5.6) 23.5 (7.6) 3.0 (−0.2 to 6.1) 0.064
TE=total energy.
*Adjusted for age, sex, and baseline measurements.
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thepreciseproportionsoftotalenergyprovidedbythe
major macronutrients. For people who prefer a rather
higher intake of fat, a Mediterranean-type diet is per-
fectly acceptable provided the fat sources are derived
from monounsaturated and polyunsaturated oils. The
guidelinescanthustakeculturalpracticesandpersonal
preferences into account, and a traditional Mediterra-
nean-type diet is as acceptable as a low fat diet rich in
minimally processed carbohydrate containing foods.
The diversity of options, compatible with the guide-
lines of the American Diabetes Association, should
enhance adherence.
36
These observations should not be taken in any way
as a suggestion that achieving substantial dietary
change to the extent that will be associated with
demonstrable reduction in risk is an easy task. A spe-
cialist health professional, usually a dietitian, is almost
always needed to enthuse the patients and to translate
thenutritionalrecommendationsintopracticaladvice.
However, the extent of the improvement in glycaemic
control seen in this trial should encourage patients to
modify their eating habits, even though this will for
many involve quite substantial change from current
practice. This requires not only expert advice but also
support from the family and an environment that
enables appropriate food choices.
37
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